Higher efavirenz plasma levels correlate with development of insomnia [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 4, 2001, Pages 399-

  Núñez, Marina ^a   De Requena, Daniel González ^a   Gallego, Lucía ^a   Jiménez Nácher, Inmaculada ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ;

CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; INCIDENCE; INSOMNIA; LETTER; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL ANALYSIS; VERTIGO;

EID: 0035576377     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200112010-00015     Document Type: Letter

References (6)

1. Non nucleoside reverse transcriptase inhibitors
2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
3. Toxicity associated to efavirenz in HIV-infected patients enrolled in an expanded access program
4. Efavirenz plasma levels can predict treatment failure and central nervous system side fects in HIV-1-infected patients
5. Quantitative determination of efavirenz (DMP266), a novel non-nucleoside verse transcriptase inhibitor, in human plasma using isocratic versed-phase high-performance liquid chromatography with ult violet detection
6. Efavirenz: Shifting the HAART paradigm in adult HIV-1 infection